Avantor® Appoints Dame Louise Makin, DBE, Ph.D., to its Board of Directors
Avantor (NYSE: AVTR) has appointed Dame Louise Makin to its Board of Directors, effective until the 2025 Annual Meeting of Stockholders. Dame Louise, former CEO of BTG plc for 15 years, brings significant healthcare industry experience, having led BTG's transformation through organic growth and acquisitions until its acquisition by Boston Scientific in 2019. She previously held leadership positions at Baxter Healthcare, including President of Biopharmaceuticals Europe. Currently, she serves as non-executive chair of Halma plc and has served on multiple corporate boards. Dame Louise holds a Ph.D. in material sciences from Cambridge and an MBA from The Open University.
Avantor (NYSE: AVTR) ha nominato Dame Louise Makin nel suo Consiglio di Amministrazione, con effetto fino all'Assemblea Annuale degli Azionisti del 2025. Dame Louise, ex CEO di BTG plc per 15 anni, porta un'esperienza significativa nel settore sanitario, avendo guidato la trasformazione di BTG attraverso crescita organica e acquisizioni fino all'acquisizione da parte di Boston Scientific nel 2019. In precedenza, ha ricoperto ruoli dirigenziali presso Baxter Healthcare, incluso quello di Presidente di Biotech Europe. Attualmente, è presidente non esecutivo di Halma plc e ha fatto parte di diversi consigli di amministrazione. Dame Louise ha conseguito un dottorato in scienze dei materiali presso Cambridge e un MBA presso The Open University.
Avantor (NYSE: AVTR) ha nombrado a Dame Louise Makin en su Junta Directiva, con efectos hasta la Junta Anual de Accionistas de 2025. Dame Louise, ex CEO de BTG plc durante 15 años, aporta una experiencia significativa en la industria de la salud, habiendo liderado la transformación de BTG a través del crecimiento orgánico y adquisiciones hasta su adquisición por Boston Scientific en 2019. Anteriormente, ocupó posiciones de liderazgo en Baxter Healthcare, incluyendo Presidenta de Biofarmacéuticos Europa. Actualmente, se desempeña como presidenta no ejecutiva de Halma plc y ha servido en múltiples juntas corporativas. Dame Louise tiene un doctorado en ciencias de materiales de Cambridge y un MBA de The Open University.
Avantor (NYSE: AVTR)는 Dame Louise Makin을 이사회의 일원으로 임명하였으며, 이는 2025년 주주 총회까지 유효합니다. Dame Louise는 BTG plc의 CEO로 15년 간 재직하며, 2019년 Boston Scientific에 인수될 때까지 BTG의 유기적 성장과 인수를 통해 변화를 이끌어 낸 경험이 있습니다. 그녀는 이전에 Baxter Healthcare에서 생물약품 유럽의 회장을 포함한 여러 리더십 직위를 역임했습니다. 현재 그녀는 Halma plc의 비상임 의장을 맡고 있으며 여러 기업 이사회에서 활동해왔습니다. Dame Louise는 캠브리지에서 재료 과학 박사 학위를, The Open University에서 MBA를 취득했습니다.
Avantor (NYSE: AVTR) a nommé Dame Louise Makin au sein de son Conseil d'Administration, avec effet jusqu'à l'Assemblée Générale Annuelle des Actionnaires de 2025. Dame Louise, ancienne PDG de BTG plc pendant 15 ans, apporte une expérience significative dans l'industrie de la santé, ayant dirigé la transformation de BTG par la croissance organique et les acquisitions jusqu'à son acquisition par Boston Scientific en 2019. Auparavant, elle a occupé des postes de direction chez Baxter Healthcare, y compris celui de Présidente des Biopharmaceutiques Europe. Actuellement, elle est présidente non exécutive de Halma plc et a siégé dans plusieurs conseils d'administration. Dame Louise détient un doctorat en sciences des matériaux de Cambridge et un MBA de l'Open University.
Avantor (NYSE: AVTR) hat Dame Louise Makin in seinen Vorstand berufen, mit Wirkung bis zur Jahreshauptversammlung der Aktionäre 2025. Dame Louise, die 15 Jahre CEO von BTG plc war, bringt umfangreiche Erfahrungen aus der Gesundheitsbranche mit und hat die Transformation von BTG durch organisches Wachstum und Akquisitionen bis zur Übernahme durch Boston Scientific im Jahr 2019 geleitet. Zuvor hatte sie Führungspositionen bei Baxter Healthcare inne, darunter die der Präsidentin der Biopharmazeutika Europa. Derzeit ist sie nicht geschäftsführende Vorsitzende von Halma plc und war in mehreren Unternehmensvorständen tätig. Dame Louise hat einen Doktortitel in Materialwissenschaften von Cambridge und einen MBA von der Open University.
- Strategic board appointment bringing extensive life sciences industry leadership experience
- Addition of director with proven track record in healthcare company transformation and growth
- Enhancement of board diversity and expertise in relevant industry sectors
- None.
Dame Louise brings a wealth of leadership and industry experience to the Avantor Board. She served as Chief Executive Officer of BTG plc, an international specialist healthcare company, for 15 years and led their transformation through organic growth and acquisitions. The company was acquired by Boston Scientific in 2019. Earlier in her career, she held several leadership positions at Baxter Healthcare, most recently as President of Biopharmaceuticals Europe.
"Dame Louise has a proven track record of success in the life sciences industry, and we are excited to welcome her to the Avantor Board of Directors," said Jonathan Peacock, Chairman of the Avantor Board. "Her addition further demonstrates Avantor's commitment to ensuring we have a diverse Board, with the right mix of skillsets and experience to drive innovation across our portfolio, advance our mission, and create long-term shareholder value."
"It is an honor to join the Avantor Board of Directors, and I look forward to working closely with the board and executive team to further strengthen the company's position as a leader in the life sciences and advanced technologies industries," said Dame Louise. "Avantor's global reach, innovative products, and services uniquely position it to drive advancements at every stage of the scientific journey and deliver differentiated value to its many stakeholders."
"Dame Louise is an excellent addition to our Board. I welcome her insights and expertise as we continue to execute our strategic plan to drive long-term growth and value creation," said Michael Stubblefield, Avantor President and Chief Executive Officer.
Dame Louise currently serves as non-executive chair of the Halma plc Board of Directors and has served as a Non-Executive Director on the Boards of Premier Foods plc, Intertek Group plc, Woodford Patient Capital Trust, Atotech Ltd., and Theramex Ltd. She was also a Trustee of The Outward Bound Trust for 10 years and Chair of the 1851 Trust for five years.
Dame Louise is an Honorary Fellow of
About Avantor
Avantor® is a leading life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. We work side-by-side with customers at every step of the scientific journey to enable breakthroughs in medicine, healthcare, and technology. Our portfolio is used in virtually every stage of the most important research, development and production activities at more than 300,000 customer locations in 180 countries. For more information, visit avantorsciences.com and find us on LinkedIn, X (Twitter) and Facebook.
Global Media Contact
Eric Van Zanten
Head of External Communications
Avantor
610-529-6219
Eric.VanZanten@avantorsciences.com
Investor Relations Contact
Christina Jones
Vice President, Investor Relations
Avantor
805-617-5297
Christina.Jones@avantorsciences.com
View original content:https://www.prnewswire.com/news-releases/avantor-appoints-dame-louise-makin-dbe-phd-to-its-board-of-directors-302297011.html
SOURCE Avantor and Financial News
FAQ
Who is Dame Louise Makin and when was she appointed to Avantor's (AVTR) board?
What is Dame Louise Makin's experience in the life sciences industry before joining Avantor (AVTR)?
What other board positions does Dame Louise Makin hold while serving on Avantor's (AVTR) board?
